EAU 2025
EAU 2025
EAU 2025: Matching-Adjusted Indirect Comparison between Enzalutamide and Darolutamide Doublet Therapy for mHSPC
- Details
(UroToday.com) The 2025 EAU annual meeting featured a prostate cancer session and a presentation by Dr. Bhavik Pandya discussing a matching-adjusted indirect comparison between enzalutamide and darolutamide doublet therapy for metastatic hormone sensitive prostate cancer (mHSPC). Enzalutamide and darolutamide are androgen receptor pathway inhibitors used as treatment options (as doublet therapy in combination with ADT) for patients with mHSPC. In the phase 3 ARCHES double blind randomized controlled trial in patients with mHSPC, enzalutamide + ADT significantly reduced the risk of metastatic progression or death compared to placebo + ADT.1 In the phase 3 ARANOTE double blind randomized controlled trial in patients with mHSPC without prior use of chemotherapy (including docetaxel) or immunotherapy, darolutamide + ADT significantly delayed radiographic progression or death compared to placebo + ADT. Adverse events occurring in >10% of patients receiving enzalutamide + ADT in ARCHES included hot flashes (27.1%), fatigue (19.6%), and arthralgia (12.2%). Adverse events occurring in >10% of patients receiving darolutamide + ADT in ARANOTE included anemia (20.4%), arthralgia (12.4%), and urinary tract infection (11.7%). Of note, there was a similar rate of discontinuation due to adverse events in patients receiving enzalutamide + ADT (7.2%) compared with patients receiving darolutamide + ADT (6.1%).
EAU 2025: A Case of Progression After Triplet Therapy for mHSPC: Evidence for and Against a Second Taxane
- Details
(UroToday.com) The 2025 EAU annual meeting featured a session on managing metastatic castration resistant prostate cancer (mCRPC) after triplet therapy for metastatic hormone sensitive prostate cancer (mHSPC) and a presentation by Dr. Jan Oldenburg discussing the evidence for and against a second taxane. Dr. Oldenburg started his presentation by noting that androgen receptor pathway inhibitor induced resistance can be overcome by taxanes. To discuss docetaxel rechallenge, Dr. Oldenburg highlighted a retrospective analysis of men treated with docetaxel for mHSPC and then rechallenged in the mCRPC setting from four cancer centers in Ontario, Canada. Among 54 evaluable patients, 27.8% had a PSA decline ≥50%, median progression free survival was 4.1 months (95% CI, 2.1-4.8) and median overall survival from ADT initiation was 38.3 months (95% CI, 32.9-41.0). The following is a waterfall plot from this study showing PSA response at docetaxel rechallenge:
EAU 2025: A Case of Progression after Triplet Therapy for mHSPC: PARP Inhibitors Alone or in Combination?
- Details
(UroToday.com) The 2025 EAU annual meeting featured a session on managing metastatic castration resistant prostate cancer (mCRPC) after triplet therapy for metastatic hormone sensitive prostate cancer (mHSPC) and a presentation by Dr. Niven Mehra discussing utilization of PARP inhibitors alone or in combination. Dr. Mehra started his presentation by emphasizing the importance of biomarker testing, given that many genes in the HRR pathway are involved in prostate cancer. The following shows the HRR pathway gene hierarchy and the effect of a single gene alteration on HRR:
EAU 2025: First-in-Human Study of RAG-01, a Novel Small Activating RNA Therapeutic in BCG Failure NMIBC Patients
- Details
(UroToday.com) The 2025 EAU annual meeting featured a non muscle invasive bladder cancer session and a presentation by Dr. Paul Anderson discussing a first-in-human study of RAG-01, a novel small activating RNA therapeutic in BCG failure non muscle invasive bladder cancer patients. Targeting the p21WAF1/CIP1 (p21) gene represents a promising yet challenging therapeutic strategy in cancer treatment. p21, a critical cell cycle inhibitor with significant tumor suppressive potential, has remained largely "undruggable" for conventional modalities. RAG-01 introduces a novel approach using small activating RNA technology to directly upregulate p21 gene expression at the transcriptional level via the RNA activating mechanism:
EAU 2025: State-of-the-art Lecture: Risk Stratification for Patients with mRCC – Is There a Need for New Approaches?
- Details
(UroToday.com) The 2025 European Association of Urology (EAU) Annual Congress held in Madrid, Spain between March 21st and 24th 2025, was host to a thematic session on hot topics in the management of renal cell carcinoma (RCC) patients. Dr. Geraldine Pignot discussed the need for new approaches to the risk stratification of patients with metastatic RCC (mRCC).
EAU 2025: State-of-the-Art Lecture: Neoadjuvant Strategies in Locally Advanced Renal Cancer
- Details
(UroToday.com) The 2025 European Association of Urology (EAU) Annual Congress held in Madrid, Spain, between March 21st and 24th 2025, was host to a thematic session on hot topics in the management of renal cell carcinoma (RCC) patients. Dr. Axel Bex discussed neoadjuvant strategies in locally advanced RCC.
EAU 2025: Debate – Renal Biopsy for Suspected Renal Cell Carcinoma
- Details
(UroToday.com) The 2025 European Association of Urology (EAU) Annual Congress held in Madrid, Spain, between March 21st and 24th, 2025, was host to a thematic session on hot topics in the management of renal cell carcinoma (RCC) patients. Drs. Anders Kjellman and Charles-Karim Bensalah debated whether patients with imaging findings suspicious for RCC should routinely undergo a renal mass biopsy (RMB).
EAU 2025: A Case of Progression After Triplet Therapy for mHSPC: LuPSMA, Who and When?
- Details
(UroToday.com) The 2025 EAU annual meeting featured a session on managing metastatic castration resistant prostate cancer (mCRPC) after triplet therapy for metastatic hormone sensitive prostate cancer (mHSPC) and a presentation by Dr. Wolfgang Fendler discussing when we should be using LuPSMA. Dr. Fendler started his presentation stating that the combination of radioligands for diagnostics and therapy have led to the field of theranostics.
EAU 2025: A Case of Progression After Triplet Therapy for mHSPC: Evidence for and Against a Second ARPI
- Details
(UroToday.com) The 2025 EAU annual meeting featured a session on managing metastatic castration resistant prostate cancer (mCRPC) after triplet therapy for metastatic hormone sensitive prostate cancer (mHSPC) and a presentation by Dr. Bertrand Tombal discussing the evidence for and against a second androgen receptor pathway inhibitor. Currently, back to back androgen receptor pathway inhibitors are widely used in the treatment of mCRPC. Barata and colleagues1 recently looked at mCRPC treatment patterns among patients across 5 European countries who received treatment with a novel hormonal therapy in the mHSPC setting (n = 76), noting that the most common first line treatment in the mCRPC setting was abiraterone:
EAU 2025: A Case of Progression After Triplet Therapy for mHSPC: Aggressive Variants
- Details
(UroToday.com) The 2025 EAU annual meeting featured a session on managing metastatic castration resistant prostate cancer (mCRPC) after triplet therapy for metastatic hormone sensitive prostate cancer (mHSPC) and a presentation by Dr. Himisha Beltran discussing aggressive variants. After triplet therapy, there are several treatment options available, including (i) an androgen receptor pathway inhibitor switch, (ii) Lu-PSMA-617, (iii) PARP inhibitor, (iv) radium-223, and (v) cabazitaxel.
EAU 2025: Discussant: PSA Response with Darolutamide plus ADT in Patients with mHSPC in ARANOTE
- Details
(UroToday.com) The 2025 EAU annual meeting featured a game changer session and a discussant presentation by Dr. Elena Castro discussing “PSA response with darolutamide plus ADT in patients with mHSPC in ARANOTE” presented by Dr. Fred Saad. In ARANOTE, patients on darolutamide who achieved an undetectable PSA had a lower risk of radiological progression or death compared to patients on darolutamide who did not achieve an undetectable PSA (HR 0.19, 95% CI 0.13-0.27):
EAU 2025: Management of Locally Advanced Prostate Cancer: What Is the Standard of Care in 2025? Intensified Approaches with Radiation Therapy
- Details
(UroToday.com) The 2025 European Association of Urology (EAU) Annual Congress held in Madrid, Spain was host to a thematic session on clinically relevant questions in the management of advanced, hormone-sensitive prostate cancer. Dr. Noel Clarke discussed the use of intensified approaches with radiation therapy for the contemporary management of locally advanced prostate cancer.
EAU 2025: My Algorithm for Decision Making in mCRPC
- Details
(UroToday.com) The 2025 EAU annual meeting featured a session on managing metastatic castration resistant prostate cancer (mCRPC) after triplet therapy for metastatic hormone sensitive prostate cancer (mHPSC) and a presentation by Dr. Christopher Sweeney discussing his algorithm for decision making in mCRPC.
EAU 2025: Updated Clinical & Translational Results: BOND-003 Cohort C: A Phase 3, Single-Arm Study of Intravesical Cretostimogene Grenadenorepvec for High-Risk BCG-Unresponsive NMIBC with CIS
- Details
(UroToday.com) The 2025 EAU annual meeting featured a non muscle invasive bladder cancer session and a presentation by Dr. Trinity Bivalacqua discussing updated clinical and translational results from BOND-003 cohort C, a phase 3, single-arm study of intravesical cretostimogene grenadenorepvec for high-risk BCG-unresponsive non muscle invasive bladder cancer with CIS. There is a significant unmet need for clinically effective and well-tolerated bladder-sparing treatments in these high risk patients. Cretostimogene grenadenorepvec is an oncolytic immunotherapy with a dual mechanism of action. It selectively replicates in and lyses cancer cells with Rb-E2F pathway alterations, which releases virus- and tumor-specific antigens, triggering antitumor immune activation, potentiated by the GM-CSF transgene:
EAU 2025: Cost-Effectiveness Analysis of Treatments for BCG-Unresponsive High-Risk NMIBC
- Details
(UroToday.com) The 2025 EAU annual meeting featured a non muscle invasive bladder cancer session and a presentation by Dr. Amanda Myers discussing cost-effectiveness analysis of treatments for BCG-unresponsive high-risk non muscle invasive bladder. Since 2021, the FDA has approved three therapies: pembrolizumab, nadofaragene firadenovec, and nogapendekin alfa inbakicept for patients with "BCG-unresponsive" disease.
EAU 2025: A Case of Progression After Triplet Therapy for mHSPC: Radium-223 Alone or in Combination
- Details
(UroToday.com) The 2025 EAU annual meeting featured a session on managing metastatic castration resistant prostate cancer (mCRPC) after triplet therapy for metastatic hormone sensitive prostate cancer (mHPSC) and a presentation by Dr. Fred Saad discussing the utility of radium-223 alone or in combination. There are no phase 3 studies that have clearly demonstrated the best approach after triplet therapy, with available options including cabazitaxel, lutetium, PARP inhibitors +/- an androgen receptor pathway inhibitor (if BRCA or HRR mutation present), and radium-223 (as long as there is no visceral disease). Ideally, eligible patients will be exposed to all available options.
Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy
- Details
- Latest BOND-003 data show 75.5% of patients achieved a complete response at any time
- Median duration of response exceeds 28 months and is ongoing
- No close contact precautions needed post cretostimogene treatment
Reno, Nevada (UroToday.com) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, announced that 83 out of 110 patients (75.5%) achieved a complete response (CR) at any time in a Phase 3 study of cretostimogene monotherapy for high-risk BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ (CIS). As of the data cutoff of January 20, 2025, 46% of patients were in CR at 12 months, with 30 confirmed responses at 24 months, with the data continuing to mature. The median duration of response (DoR) has not been reached but exceeds 28 months. These data from BOND-003 Cohort C were presented today as a late-breaking abstract at the 40th Annual European Association of Urology (EAU) Congress taking place in Madrid, Spain.
EAU 2025: Debate – Management of Recurrence After Curative Surgery: What is the New Standard of Care? Surgical Resection, Tyrosine Kinase Inhibitors, Immunotherapy, or Radiotherapy?
- Details
(UroToday.com) The 2025 European Association of Urology (EAU) Annual Congress held in Madrid, Spain between March 21st and 24th 2025, was host to a thematic session on hot topics in the management of renal cell carcinoma (RCC) patients. Drs. Petrus Järvinen, Laurence Albiges, Cristina Suárez, and Dr. Ben Vanneste debated the optimal strategy for the management of recurrences after curative surgery for RCC: surgical resection, tyrosine kinase inhibitors (TKIs), immunotherapy, and radiotherapy.
EAU 2025: Prehabilitation: Diet, Sleep and Psychological Preparation
- Details
(UroToday.com) The 2025 EAU annual meeting featured a plenary session on optimizing the patient journey and a presentation by Dr. Karl-Friedrich Kowalewski discussing the impact of diet, sleep, and psychological preparation on prehabilitation. Dr. Kowalewski started his presentation emphasizing that there is a body of evidence to support optimization of nutrition during prehabilitation, which has been shown to be beneficial in reducing complications. For example, in a 2013 meta-analysis of randomized controlled trials on preoperative oral carbohydrate treatment in elective surgery, a 50 g oral carbohydrate intervention on the morning of surgery was shown to potentially reduce length of post-operative stay. Dr. Kowalewski notes that there are several key aspects for a nutrition intervention as part of prehabilitation:
EAU 2025: Prehabilitation: The Impact of Exercise, Personalized Programs, and Digital Devices
- Details
(UroToday.com) The 2025 EAU annual meeting featured a plenary session on optimizing the patient journey and a presentation by Dr. Sarah Psutka discussing the impact of exercise, personalized programs, and digital devices on prehabilitation. Dr. Psutka started her presentation by defining prehabilitation as a process of improving the functional capability of a patient prior to a surgical procedure/medical treatment so that the patient can withstand treatment-associated functional decline/physiologic insult. At the core of prehabilitation are several domains, including mental, nutritional, and physical. Resilience is defined as an individual’s ability to maintain psychological and physical functioning in the face of stressors. Thus, the hype is: “can we make our patients more resilient to the stresses of surgery with exercise prehabilitation?”